Functional: Pharmacological Management of LUTS: Difference between revisions

← Older edit Newer edit →

VisualWikitext

@@ Line 265: / Line 265: @@
 **'''<span style="color:#ff0000">Not FDA-approved in non-neurogenic OAB patients, 100U typically used</span>'''
 *'''<span style="color:#ff0000">Contraindications (4):</span>'''
-*# '''<span style="color:#ff0000">Active UTI</span>'''
+*# '''<span style="color:#ff0000">Active urinary tract infection</span>'''
 *# '''<span style="color:#ff0000">Acute urinary retention</span>'''
 *# '''<span style="color:#ff0000">Unwillingness or inability to self-catheterize</span>'''
 *# '''<span style="color:#ff0000">Hypersensitivity</span>'''
 * '''<span style="color:#ff0000">Adverse events:</span>'''
-** '''<span style="color:#ff0000">Most common: bladder pain and urinary infections. Hematuria, usually mild, may also occur'''
+**'''<span style="color:#ff0000">Most common (3):</span>'''
-** '''Most serious: paralysis of the striated musculature caused by circulatory leakage of the toxin'''
+**#'''<span style="color:#ff0000">Bladder pain</span>'''
-*** Has never been reported.
+**#'''<span style="color:#ff0000">Gross hematuria (usually mild)</span>'''
-**** '''Caution should be used in treating high-risk patients, including:'''
+**# '''<span style="color:#ff0000">Urinary tract infection</span>'''
-****# '''Children'''
+**'''<span style="color:#ff0000">Most serious (2):</span>'''
-****# '''Patients with low pulmonary reserve'''
+**#'''<span style="color:#ff0000">Urinary retention and a transient necessity to perform CIC</span>'''
-****# '''Patients with myasthenia gravis'''
+**#*<span style="color:#ff0000">'''Patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary'''
-*** '''Transient muscle weakness''' was reported with abobotA application
+**#*'''The proportion of patients who initiate CIC at any time during treatment cycle 1 was 6.1%''' versus none in the placebo group; for over half the patients who initiated CIC, the duration of CIC was 6 weeks or less.
-** '''Most feared in patients with voluntary voiding: urinary retention and a transient necessity to perform CIC.'''
+**#'''Paralysis of the striated musculature caused by circulatory leakage of the toxin'''
-*** '''The proportion of patients who initiate CIC at any time during treatment cycle 1 was 6.1%''' versus none in the placebo group; for over half the patients who initiated CIC, the duration of CIC was 6 weeks or less.
+**#* '''Has never been reported.'''
+**#** '''Caution should be used in treating high-risk patients, including:'''
+**#**# '''Children'''
+**#**# '''Patients with low pulmonary reserve'''
+**#**# '''Patients with myasthenia gravis'''
+**#* '''Transient muscle weakness''' was reported with abobotA application
+**'''<span style="color:#ff0000">Other:</span>'''
+**#'''<span style="color:#ff0000">Dry mouth</span>'''
+**#'''<span style="color:#ff0000">Dysphagia</span>'''
+**#'''<span style="color:#ff0000">Impaired vision</span>'''
+**# '''<span style="color:#ff0000">Eyelid weakness</span>'''
+**#'''<span style="color:#ff0000">Arm weakness</span>'''
+**#'''<span style="color:#ff0000">Leg weakness</span>'''
+**# '''<span style="color:#ff0000">Torso weakness</span>'''
 ** '''Aminoglycosides should be avoided during BoNTA treatment because they might block motor plates and therefore enhance BoNTA effect'''